| Policy papers |
|
|
|
|
As the peak body representing the interests of the alcohol and other drug sector nationally, ADCA has a key role in advocating for adequate infrastructure support and funding for the delivery of evidence-based alcohol and other drug initiatives. ADCA advocates for the alcohol and other drugs sector by:
Policy Positions of the Alcohol and other Drugs Council of Australia (ADCA) is a comprehensive, easy to read overview of the evidence and debate and outlines ADCA's policy agenda across specific drugs and strategies. It also identifies a number of measures that can be used to monitor Australia's performance in addressing alcohol and other drug related issues. All papers in this collection were previously placed onto this website in draft form, providing the sector with an opportunity to input. ADCA would like to thank the many people who have provided feedback, as well as the work of the ADCA Board and ADCA's eight Reference Groups for their advice and assistance in preparing the papers. Please note: ADCA is reviewing its policy positions which were first published in 2003. While the principles behind ADCA's policy positions remain extant, the supporting statistics and references now need to be updated. For information on the policy updates, please contact This e-mail address is being protected from spam bots, you need JavaScript enabled to view it , ADCA's Strategic Communications and Policy Officer, on 02 6281 0686. This work is copyright. Individual papers may be reproduced in whole or part subject to the inclusion of an acknowledgement of the source and no commercial usage or sale. Reproduction for other purposes requires the written permission of ADCA. Policy Papers Foreward Specific drugs 1.1 Tobacco 1.2 Alcohol 1.3 Misuse of prescription drugs 1.4 Inhalants 1.5 Cannabis 1.6 Heroin 1.7 Amphetamine-type substances 1.8 Other drugs Measuring performance Strategies to minimise harm 2.1 Prevention 2.2 Interventions in schools 2.3 Interventions in the workplace 2.4 Treatment 2.5 Law enforcement and harm minimisation 2.6 Taxation and pricing 2.7 Needle and syringe programs 2.8 Supervised injecting centres 2.9 Research 2.10 Diversion 2.11 Workforce development |



